title: Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain.
abstract: Neuronal expression of immediate-early genes in response to a drug is a powerful screening tool for dissecting anatomical and functional brain circuitry affected by psychoactive compounds. We examined the effect of dopaminergic perturbation on two Homer 1 gene splice variants, Homer 1a and ania-3, in rat forebrain. Rats were treated with the "typical" antipsychotic haloperidol, the "atypical" quetiapine, or the selective dopamine transporter (DAT) inhibitor GBR 12909 in acute and chronic paradigms. Our results show that the high affinity dopamine D(2) receptor antagonist haloperidol strongly induces Homer 1 gene expression in the caudate-putamen, whereas quetiapine, a fast D2R dissociating antagonist, does not. This confirms that Homer 1 may be considered a predictor of "atypicality" of antipsychotic compounds in acute and also chronic regimens. Chronic treatment with GBR 12909 showed a strong induction in the parietal cortex, resembling the activation of "sensitization" circuitry by stimulants. Finally, we describe a differential spatial induction pattern of Homer 1 gene within the caudate-putamen by typical antipsychotics and DAT blockers, and propose a novel method to quantitate it.
authors: Laboratory of Molecular Psychiatry and Psychopharmacotherapy, Section of Psychiatry, Department of Neuroscience, University School of Medicine Federico II, Naples, Italy.
authors: Alberto
authors: A
authors: Ambesi-Impiombato
authors: Fabio
authors: F
authors: Panariello
authors: Carmela
authors: C
authors: Dell'aversano
authors: Carmine
authors: C
authors: Tomasetti
authors: Giovanni
authors: G
authors: Muscettola
authors: Andrea
authors: A
authors: de Bartolomeis
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001479:Basal Ganglia / Q000187:drug effects / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics*; D003987:Dibenzothiazepines / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004334:Drug Administration Schedule; D015870:Gene Expression / Q000187:drug effects* / Q000502:physiology; D006220:Haloperidol / Q000494:pharmacology; D000072233:Homer Scaffolding Proteins; D008297:Male; D010296:Parietal Lobe / Q000187:drug effects / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism*; D000069348:Quetiapine Fumarate; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D015415:Biomarkers; D002352:Carrier Proteins; D003987:Dibenzothiazepines; D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D000072233:Homer Scaffolding Proteins; D010879:Piperazines; D017448:Receptors, Dopamine D2; D000069348:Quetiapine Fumarate; C043425:vanoxerine; D006220:Haloperidol; D004298:Dopamine